New PET scan for liver and neuroendocrine tumors
Part of Cancer, Digestive system clinical trials.
This trial tests a new PET imaging method that uses two different tracers to find and stage liver cancer (HCC) or neuroendocrine tumors (GEP-NET) more accurately. It may help doctors decide on the best treatment for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of liver cancer (HCC) or a neuroendocrine tumor (GEP-NET) that has spread to the liver or pancreas
- You have at least one tumor that can be seen on a CT or MRI scan done in the last 6 months
- You are able to do your daily activities with little to no help (ECOG score 0–2)
- You are covered by French social security or a similar health plan
- You are willing to use effective birth control (if applicable) for several months after the scan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan tracer (zirconium-labelled girentuximab) to see if it can find and track certain liver, bile duct, and pancreatic/intestinal neuroendocrine tumors. It may help doctors better understand your cancer and guide treatment decisions.
This trial tests a new imaging technique that may help doctors see liver cancer more clearly. It uses a special tracer that targets a protein found on many liver cancer cells. This could help with diagnosis and monitoring.
This study tests a new imaging tracer to better see liver cancer on PET scans, which might help doctors find or monitor tumors more accurately.
This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.
This trial tests whether a new PET imaging agent (GPC3-targeted) can find liver cancer as well as or better than enhanced MRI. It may help diagnose hepatocellular carcinoma (the most common type of liver cancer) more accurately.
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.